Drugs / Pertuzumab
Pertuzumab
also known as
Perjeta · rhuMAb 2C4 · Combination product: Trastuzumab + Pertuzumab · Omnitarg · Pmab · QL1209 · QL1209 (A pertuzumab biosimilar produced by Qilu Pharmaceutical Co., Ltd) · ZRC-3277
Monoclonal antibody targets ERBB2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | PERJETA | — | 2013-04-12 – 2026-04-23 | fda.gov ↗ |
| Label expansion | US (FDA) | PHESGO | — | 2024-11-22 | fda.gov ↗ |
| Approved | EU (EMA) | Perjeta | — | 2013-03-04 | europa.eu ↗ |
| Approved | US (FDA) | PERJETA | — | 2012-06-08 | fda.gov ↗ |
Trials 208 · started per year
today
US approved 2012
EU approved 2013
1
5
2
3
3
1
1
7
4
4
5
10
15
15
12
6
8
9
15
13
11
12
12
19
14
200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05238831 | Jan 2023 → May 2026 | female breast carcinoma, ovarian carcinoma, pancreatic ductal adenocarcinoma, pancreatic large cell neuroendocrine carcinoma +2 | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
| Phase 118 trials | ||||||
| Phase 1 | NCT06162559 | Dec 2023 → Aug 2026 overdue | breast cancer | The Netherlands Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT05275010 | May 2022 → May 2023 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT05385705 | May 2022 → Jul 2024 | breast neoplasm | Vall d'Hebron Institute of Oncology | Terminated | No outcome recorded |
| Phase 1 | NCT03878524 | Apr → Dec 2020 | acute myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 negative, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, castration-resistant prostate carcinoma +14 | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT04188548 | Dec 2019 → Jun 2020 overdue | breast cancer, endometrial cancer | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03716180 | Nov 2018 → Oct 2020 overdue | breast cancer | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02598427 | May 2017 → Feb 2018 | HER2 positive breast carcinoma | Kimberly Blackwell | Terminated | No outcome recorded |
| Phase 1 | NCT03006172 | Dec 2016 → Dec 2026 expected | breast cancer | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02738970 | Jun 2016 → May 2018 | female breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02605915 | Dec 2015 → Nov 2019 | HER2 positive breast carcinoma, female breast carcinoma, triple-negative breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02390427 | Apr 2015 → Dec 2022 | breast carcinoma, metastatic neoplasm | Otto Metzger, MD | Completed | No outcome recorded |
| Phase 1 | NCT02060253 | Apr 2014 → Jun 2018 | HER2 positive breast carcinoma, male breast carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02057133 | Mar 2014 → Mar 2021 overdue | breast neoplasm | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01918254 | Aug 2013 → Oct 2016 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02507375 | Sep 2006 → Dec 2008 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02490475 | Feb 2004 → Apr 2006 | cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02494596 | Jan 2004 → Sep 2005 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT00027027 | Nov 2001 → Aug 2003 | neoplasm | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/218 trials | ||||||
| Phase 1/2 | NCT07612215 | May 2026 → May 2029 expected | triple-positive breast carcinoma | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07140393 | Oct 2025 → Oct 2027 expected | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06686394 | Feb 2025 → Apr 2030 expected | breast cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05574881 | Sep 2022 → Jan 2025 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04538742 | Dec 2020 → Jan 2025 overdue | breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04588545 | Dec 2020 → Apr 2027 expected | HER2 positive breast carcinoma, malignant tumor of meninges | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04215003 | Jan 2020 → Dec 2024 | breast cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT03881878 | May 2019 → Oct 2022 | HER2 positive breast carcinoma | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT03101748 | Feb 2018 → May 2025 | inflammatory breast carcinoma, metastatic carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT03304080 | Dec 2017 → Jul 2026 overdue | breast neoplasm | Icahn School of Medicine at Mount Sinai | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02139358 | Sep 2014 → Apr 2018 | breast cancer | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02345772 | Jul 2014 → Nov 2015 | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer | Western Regional Medical Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02336984 | Jun 2014 → Apr 2016 | breast cancer | H. Lee Moffitt Cancer Center and Research Institute | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02120911 | Jan 2014 → Feb 2017 | esophageal cancer | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 1/2 | NCT00951665 | Aug 2009 → Feb 2012 | breast cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00934856 | Jul 2009 → Oct 2013 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT00875979 | May 2009 → Aug 2011 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/2 | NCT00551421 | Oct 2007 → Nov 2010 | colon adenocarcinoma, rectum adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2119 trials | ||||||
| Phase 2 | NCT07610720 | Jun 2026 → Nov 2028 expected | HER2 positive breast carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07565324 | Apr 2026 → Dec 2029 expected | HER2 positive breast carcinoma | National Taiwan University Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07402473 | Mar 2026 → Dec 2027 expected | HER2 positive breast carcinoma | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 2 | NCT07647263 | Mar 2026 → Jun 2029 expected | HER2 positive breast carcinoma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 2 | NCT07459673 | Mar 2026 → Mar 2030 expected | HER2 positive breast carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07393425 | Feb 2026 → Sep 2027 expected | HER2 positive breast carcinoma | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT07290166 | Dec 2025 → Oct 2027 expected | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07340398 | Dec 2025 → Dec 2028 expected | HER2 positive breast carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT07299890 | Dec 2025 → Nov 2027 expected | breast cancer | Anhui Provincial Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07307287 | Dec 2025 → Dec 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Show all 119 trials opens the full record — a long page | ||||||
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT07294508 | Feb 2026 → Jan 2028 expected | HER2 positive breast carcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07294534 | Jan 2026 → Sep 2028 expected | HER2 positive breast carcinoma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06891833 | Jun 2025 → Dec 2028 expected | HER2 positive breast carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05786716 | Mar 2023 → Oct 2029 expected | cancer, colorectal neoplasm, gallbladder neoplasm, hematopoietic and lymphoid cell neoplasm +7 | Cancer Research UK | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05722886 | Mar 2023 → Oct 2029 expected | cancer, hematopoietic and lymphoid cell neoplasm | Cancer Research UK | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02581462 | Jun 2016 → Jul 2020 | gastric cancer, gastroesophageal junction adenocarcinoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Completed | No outcome recorded |
| Phase 333 trials | ||||||
| Phase 3 | NCT07683754 | Sep 2026 → Jul 2030 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer | Daiichi Sankyo | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07377643 | Feb 2026 → Apr 2028 expected | HER2 positive breast carcinoma | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Recruiting | No outcome recorded |
| Phase 3 | NCT06876714 | Sep 2025 → Mar 2028 expected | HER2 positive breast carcinoma | Alliance for Clinical Trials in Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT06490536 | Oct 2024 → Mar 2026 overdue | colorectal cancer | IFOM ETS - The AIRC Institute of Molecular Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT05883852 | Jun 2023 → Jul 2031 expected | HER2 positive breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05256225 | Nov 2022 → Oct 2027 expected | carcinosarcoma of the corpus uteri, endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial mixed adenocarcinoma +2 | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT05415215 | Jul 2022 → Nov 2024 | female breast carcinoma, inflammatory breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT05188313 | Mar 2022 → Jul 2027 expected | esophageal adenocarcinoma | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase 3 | NCT05113251 | Oct 2021 → Mar 2025 overdue | HER2 positive breast carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04784715 | Apr 2021 → Jul 2026 overdue | HER2 positive breast carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05429684 | Jan 2021 → Feb 2024 | HER2 positive breast carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 3 | NCT04547907 | Sep 2020 → Dec 2024 overdue | HER2 positive breast carcinoma | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT04514419 | Jun 2020 → Sep 2024 overdue | breast cancer | BioRay Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03803553 | Apr 2020 → Dec 2026 expected | metastasis from malignant tumor of colon | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT04193059 | Dec 2019 → Jul 2026 overdue | breast cancer | Fudan University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03811418 | Jan → Apr 2019 | HER2 positive breast carcinoma, female breast carcinoma | iOMEDICO AG | Withdrawn | No outcome recorded |
| Phase 3 | NCT04957212 | Aug 2018 → May 2020 | HER2 positive breast carcinoma | Cinnagen | Completed | No outcome recorded |
| Phase 3 | NCT03264547 | Aug 2017 → Dec 2024 | breast cancer | Japan Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 3 | NCT02896855 | Sep 2016 → Jun 2018 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02586025 | Mar 2016 → Oct 2017 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02625441 | Dec 2015 → Jun 2025 overdue | breast cancer | Helsinki University Central Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02514681 | Aug 2015 → Dec 2018 | HER2 positive breast carcinoma | Japan Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 3 | NCT02320435 | Feb 2015 → Dec 2026 expected | cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02125344 | Dec 2014 → Nov 2016 | HER2 positive breast carcinoma, breast mucinous carcinoma, female breast carcinoma, inflammatory breast carcinoma +1 | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 3 | NCT02131064 | Jun 2014 → Dec 2015 | breast neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02019277 | Dec 2013 → Nov 2016 | female breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01774786 | Jun 2013 → Dec 2016 | gastric cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01684878 | Oct 2012 → Jan 2015 | ovarian cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01572038 | Jun 2012 → Sep 2019 | breast neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01358877 | Nov 2011 → Dec 2016 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01120184 | Jul 2010 → Sep 2014 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01026142 | Jan 2010 → May 2015 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00567190 | Feb 2008 → May 2011 | breast cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT07695259 | May 2026 → Dec 2027 expected | HER2 positive breast carcinoma | Wen-Ming Cao | Recruiting | No outcome recorded |
| Phase 4 | NCT06641544 | Oct 2024 → Dec 2027 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 4 | NCT06578299 | Aug 2024 → Mar 2026 overdue | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT02445586 | Aug 2015 → Sep 2018 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT07589972 | Apr 2026 → Dec 2027 expected | breast carcinoma by gene expression profile | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07377916 | Feb 2026 → Jun 2029 expected | non-small cell lung carcinoma | The First Affiliated Hospital of Guangzhou Medical University | Not yet recruiting | No outcome recorded |
| — | NCT07187752 | Sep 2025 → Dec 2026 expected | breast cancer | Shandong Cancer Hospital and Institute | Not yet recruiting | No outcome recorded |
| — | NCT07095023 | Aug 2025 → Dec 2026 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| — | NCT05656079 | Jul 2021 → Sep 2024 | breast cancer | Shanghai Pudong Hospital | Unknown | No outcome recorded |
| — | NCT07115095 | Jan 2021 → Jan 2023 | HER2 positive breast carcinoma | Nanlin Li | Completed | No outcome recorded |
| — | NCT06907082 | Dec 2020 → Mar 2024 | breast cancer | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | Completed | No outcome recorded |
| — | NCT01048099 | Jan 2011 → Jul 2014 | breast cancer | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04395508 | — | HER2 positive breast carcinoma | Genentech, Inc. | Approved for marketing | No outcome recorded |
Also used as a comparator or background therapy in 121 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03387553 Background | Jun 2018 → Aug 2023 | HER2 positive breast carcinoma, female breast carcinoma, invasive breast carcinoma, male breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 0 | NCT01875666 Comparator | Aug 2013 → Dec 2016 | breast neoplasm | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT05825781 Comparator | Jul 2023 → Jan 2024 overdue | — | Mabscale, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05738993 Comparator | Aug 2022 → Apr 2023 | breast cancer | Biocad | Unknown | No outcome recorded |
| Phase 1 | NCT05471648 Comparator | May 2022 → Jan 2023 | breast cancer | EirGenix, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05323981 Comparator | Apr → Oct 2022 | — | BioRay Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04820439 Comparator | Oct 2020 → Feb 2021 | — | The Affiliated Hospital of Qingdao University | Completed | No outcome recorded |
| Phase 1 | NCT04411550 Comparator | Jul 2020 → Jul 2021 | — | Shanghai Henlius Biotech | Completed | No outcome recorded |
| Phase 1 | NCT04253561 Background | Feb 2020 → Dec 2021 | breast cancer | SOLTI Breast Cancer Research Group | Completed | No outcome recorded |
| Phase 1 | NCT03135171 Background | Jul 2017 → Mar 2020 | breast cancer | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02593708 Background | Nov 2015 → Jan 2017 | cancer | Michelle Melisko | Terminated | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT06771622 Background | Mar 2025 → Jan 2028 expected | — | FBD Biologics Limited | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05256745 Background | Jun 2023 → Dec 2026 expected | breast cancer, subjective cognitive decline | Georgetown University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05319873 Comparator | Apr 2022 → Apr 2027 expected | HER2 positive breast carcinoma, invasive breast carcinoma | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05150691 Background | Jan 2022 → Apr 2026 overdue | — | DualityBio Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04108858 Background | May 2021 → Apr 2022 | HER2 positive breast carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT04750122 Background | Mar 2021 → Jun 2022 overdue | HER2 positive breast carcinoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05593094 Background | Sep 2020 → Aug 2027 expected | HER2 positive breast carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT01922921 Background | Feb 2014 → Oct 2019 | HER2 positive breast carcinoma | University of Washington | Completed | No outcome recorded |
| Phase 1/2 | NCT02379585 Comparator | Jan 2013 → Aug 2015 | HER2 positive breast carcinoma | Western Regional Medical Center | Terminated | No outcome recorded |
| Phase 252 trials | ||||||
| Phase 2 | NCT07679269 Background | Jan 2027 → Jun 2031 expected | PIK3CA-related overgrowth spectrum, breast neoplasm | Novartis Pharmaceuticals | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07581795 Background | Jun 2026 → Feb 2029 expected | HER2 positive breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07545044 Comparator | May 2026 → May 2027 expected | HER2 positive breast carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07616427 Background | May 2026 → May 2028 expected | HER2 positive breast carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT07550972 Comparator | May 2026 → Mar 2030 expected | head and neck squamous cell carcinoma | Zhejiang Provincial People's Hospital | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT07527806 Background | May 2026 → May 2029 expected | breast cancer | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07528898 Background | May 2026 → Jul 2027 expected | breast cancer | Hebei Medical University Fourth Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07371585 Background | Feb 2026 → Aug 2029 expected | breast cancer | SOLTI Breast Cancer Research Group | Recruiting | No outcome recorded |
| Phase 2 | NCT07245797 Background | Dec 2025 → Dec 2026 expected | breast cancer | Zhimin Shao | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07246317 Background | Dec 2025 → Dec 2027 expected | breast cancer | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07220135 Background | Nov 2025 → Nov 2027 expected | breast cancer | University of Kansas Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07102381 Comparator | Sep 2025 → Jan 2028 expected | HER2 positive breast carcinoma | Jazz Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT07053085 Comparator | Sep 2025 → Sep 2029 expected | HER2 positive breast carcinoma, metastatic malignant neoplasm | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07116824 Background | Sep 2025 → Jul 2026 overdue | HER2 positive breast carcinoma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07136974 Comparator | Sep 2025 → Aug 2028 expected | HER2 positive breast carcinoma | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06548178 Comparator | Sep 2024 → Sep 2025 overdue | HER2 positive breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06178159 Background | Nov 2023 → Jun 2026 overdue | breast cancer | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05978648 Background | Sep 2023 → Dec 2026 expected | breast cancer | wang shusen | Recruiting | No outcome recorded |
| Phase 2 | NCT07421141 Background | Sep 2023 → Dec 2025 overdue | HER2 positive breast carcinoma | National Medical Research Radiological Centre of the Ministry of Health of Russia | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05020860 Comparator | Apr 2023 → Aug 2027 expected | HER2 positive breast carcinoma, female breast carcinoma, hormone receptor-positive breast cancer, invasive breast carcinoma +1 | Baylor Breast Care Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05323955 Background | Mar 2023 → Nov 2026 expected | HER2 positive breast carcinoma, metastatic malignant neoplasm in the brain | Carey Anders, M.D. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05638594 Comparator | Dec 2022 → Dec 2025 overdue | breast cancer | Shengjing Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04329065 Background | Apr 2022 → Dec 2026 expected | female breast carcinoma | University of Washington | Recruiting | No outcome recorded |
| Phase 2 | NCT05041842 Background | Dec 2021 → Apr 2025 overdue | metastatic malignant neoplasm in the brain | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05325632 Background | Oct 2021 → Feb 2027 expected | HER2 positive breast carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT05483439 Background | Oct 2021 → Jul 2023 | breast cancer | Shengjing Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04760431 Comparator | Oct 2021 → Sep 2024 | HER2 positive breast carcinoma, metastatic malignant neoplasm in the brain | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 2 | NCT05292742 Comparator | Jul 2021 → Oct 2026 expected | breast cancer | Fujian Medical University Union Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04717531 Comparator | Jun 2021 → Jun 2023 | breast cancer | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT04900311 Comparator | May 2021 → Dec 2023 | HER2 positive breast carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04578106 Background | Sep 2020 → Jul 2024 | HER2 positive breast carcinoma, female breast carcinoma | Fundacio Clinic Barcelona | Terminated | No outcome recorded |
| Phase 2 | NCT04301375 Background | Jun 2020 → Jul 2027 expected | breast cancer | David Garcia Cinca | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04398914 Background | May 2020 → Dec 2022 overdue | invasive breast carcinoma | Shanghai Jiao Tong University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04197687 Background | Feb 2020 → Jan 2025 | breast adenocarcinoma | Academic and Community Cancer Research United | Unknown | No outcome recorded |
| Phase 2 | NCT04246502 Comparator | Jan 2020 → Dec 2022 | breast cancer | Shandong Cancer Hospital and Institute | Unknown | No outcome recorded |
| Phase 2 | NCT03894007 Background | May 2019 → Jun 2021 | HER2 positive breast carcinoma | Renske Altena | Terminated | No outcome recorded |
| Phase 2 | NCT03644186 Background | Apr 2019 → Jan 2023 | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer | ETOP IBCSG Partners Foundation | Completed | No outcome recorded |
| Phase 2 | NCT03329378 Comparator | Jan 2019 → Mar 2021 | breast carcinoma | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded |
| Phase 2 | NCT04172259 Background | Jan 2019 → Sep 2023 overdue | breast cancer | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03058939 Background | Nov 2018 → Apr 2019 | female breast carcinoma | University of Chicago | Withdrawn | No outcome recorded |
| Phase 2 | NCT03272477 Background | Oct 2017 → Jul 2020 | breast cancer | Palleos Healthcare GmbH | Completed | No outcome recorded |
| Phase 2 | NCT03238495 Background | Aug 2017 → Jun 2022 | HER2 positive breast carcinoma | Qamar Khan | Unknown | No outcome recorded |
| Phase 2 | NCT03125928 Background | Jun 2017 → Dec 2026 expected | HER2 positive breast carcinoma | Fox Chase Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02682693 Background | Feb 2017 → Dec 2019 | HER2 positive breast carcinoma, breast mucinous carcinoma, female breast carcinoma, inflammatory breast carcinoma +1 | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 2 | NCT02909751 Background | Sep 2016 → Jan 2019 | breast cancer | Vejle Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02073487 Comparator | Feb 2014 → Jan 2019 | breast cancer | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT01597414 Comparator | Jun 2013 → Mar 2017 | breast cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 2 | NCT01835236 Comparator | Mar 2013 → Jan 2018 | breast cancer | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT01847001 Background | Oct 2012 → Dec 2018 | breast cancer | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT01042379 Comparator | Mar 2010 → Dec 2030 expected | HER2 positive breast carcinoma, angiosarcoma, female breast carcinoma, hormone receptor-positive breast cancer +1 | QuantumLeap Healthcare Collaborative | Recruiting | No outcome recorded |
| Phase 2 | NCT00781612 Background | Oct 2008 → Sep 2029 expected | metastatic neoplasm | Genentech, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00096993 Comparator | Jan 2005 → Sep 2007 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05426486 Comparator | May 2022 → Dec 2025 overdue | HER2 positive breast carcinoma | Caigang Liu | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02568839 Comparator | Nov 2014 → Feb 2019 overdue | HER2 positive breast carcinoma | Thomas Hatschek | Active not recruiting | No outcome recorded |
| Phase 341 trials | ||||||
| Phase 3 | NCT07578116 Background | Mar 2027 → May 2032 expected | HER2 positive breast carcinoma, female breast carcinoma | SWOG Cancer Research Network | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07528716 Background | May 2026 → Dec 2027 expected | breast cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT07518173 Background | Apr 2026 → Dec 2029 expected | HER2 positive breast carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07441460 Comparator | Mar 2026 → Aug 2034 expected | HER2 positive breast carcinoma | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07239271 Comparator | Nov 2025 → Dec 2027 expected | HER2 positive breast carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07196774 Comparator | Oct 2025 → Dec 2027 expected | breast carcinoma by gene expression profile | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07043725 Comparator | Sep 2025 → Sep 2027 expected | HER2 positive breast carcinoma | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07057427 Background | Jun 2025 → Jun 2028 expected | breast cancer | Henan Cancer Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT07003074 Comparator | Jun 2025 → Jul 2029 expected | breast cancer | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06884254 Comparator | May 2025 → Nov 2026 | breast cancer | EirGenix, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT06038539 Comparator | Jan → Dec 2025 | HER2 positive breast carcinoma | Biocon Biologics UK Ltd | Terminated | No outcome recorded |
| Phase 3 | NCT06747338 Comparator | Dec 2024 → Dec 2026 expected | HER2 positive breast carcinoma | Shanghai JMT-Bio Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07386938 Comparator | Aug 2024 → Oct 2025 overdue | breast cancer | R-Pharm | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06135714 Background | Nov 2023 → Nov 2026 expected | breast cancer | Tokyo Medical and Dental University | Recruiting | No outcome recorded |
| Phase 3 | NCT06057610 Comparator | Oct 2023 → Oct 2027 expected | HER2 positive breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06278870 Comparator | Sep 2023 → Jun 2031 expected | HER2 positive breast carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05838066 Comparator | Jul 2023 → Jul 2025 overdue | breast carcinoma by gene expression profile | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05760612 Comparator | Mar 2023 → Feb 2028 expected | HER2 positive breast carcinoma, female breast carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05720026 Comparator | Jan 2023 → Aug 2025 | HER2 positive breast carcinoma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05871918 Background | Oct 2022 → Dec 2023 | HER2 positive breast carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05283837 Comparator | Sep 2022 → Sep 2023 | breast cancer | Zydus Lifesciences Limited | Completed | No outcome recorded |
| Phase 3 | NCT05474690 Comparator | May 2022 → Mar 2023 | HER2 positive breast carcinoma | Henan Cancer Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT05346224 Comparator | Apr 2022 → May 2024 overdue | HER2 positive breast carcinoma | Shanghai Henlius Biotech | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05132582 Background | Mar 2022 → Sep 2025 overdue | HER2 positive breast carcinoma | Pfizer | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05159193 Comparator | Dec 2021 → Oct 2024 overdue | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT04858529 Comparator | Apr 2021 → Apr 2024 | breast carcinoma by gene expression profile | Guangdong Provincial People's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04629846 Comparator | Nov 2020 → Aug 2022 | breast cancer | Qilu Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05985187 Comparator | Oct 2020 → Jan 2023 | HER2 positive breast carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04208178 Background | Jul 2020 → Feb 2027 expected | HER2 positive breast carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04337658 Background | Jul 2020 → Apr 2024 | HER2 positive breast carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 3 | NCT04024462 Comparator | Feb 2020 → Dec 2021 | HER2 positive breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT03199885 Background | Apr 2019 → Apr 2024 | HER2 positive breast carcinoma, breast adenocarcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 3 | NCT03726879 Background | Jan 2019 → Feb 2021 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT03595592 Background | Sep 2018 → Dec 2026 expected | invasive breast carcinoma | Fondazione Michelangelo | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03493854 Comparator | Jun 2018 → Jul 2019 | female breast carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02947685 Background | Jun 2017 → Oct 2024 overdue | HER2 positive breast carcinoma, estrogen-receptor positive breast cancer | Alliance Foundation Trials, LLC. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02344472 Background | Sep 2015 → Jan 2025 | breast cancer | University of Ulm | Unknown | No outcome recorded |
| Phase 3 | NCT02402712 Background | May 2015 → Feb 2019 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT02003209 Background | Feb 2014 → Oct 2016 | HER2 positive breast carcinoma, hormone receptor-positive breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT01966471 Comparator | Jan 2014 → Nov 2019 | breast cancer | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01996267 Comparator | Dec 2013 → Dec 2018 overdue | HER2 positive breast carcinoma | The Netherlands Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT07093931 Background | Aug 2025 → Aug 2027 expected | breast cancer | Shandong Cancer Hospital and Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05420467 Background | Jul 2022 → Jul 2027 expected | breast cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 4 | NCT05420454 Background | Jul 2022 → Jun 2027 expected | breast cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 4 | NCT05036005 Background | Jul 2021 → Apr 2023 | HER2 positive breast carcinoma, female breast carcinoma | Institut fuer Frauengesundheit | Unknown | No outcome recorded |
| Phase 4 | NCT01501487 Comparator | Oct 2011 → Feb 2016 | breast cancer | Agendia | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06190600 Background | Oct 2018 → Mar 2020 overdue | female breast carcinoma | The Greater Poland Cancer Centre | Active not recruiting | No outcome recorded |
Press releases naming this drug 25 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-24 | AstraZeneca | Enhertu plus pertuzumab recommended for approval in the EU by CHMP as 1st-line treatment for patients with HER2-positive metastatic breast cancer astrazeneca.com ↗ |
| 2026-04-29 | Organon and Co | European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe organon.com ↗ |
| 2025-12-15 | AstraZeneca | Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer astrazeneca.com ↗ |
| 2025-11-17 | Organon and Co | Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US organon.com ↗ |
| 2025-09-24 | AstraZeneca | Enhertu plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer astrazeneca.com ↗ |
| 2025-06-02 | AstraZeneca | Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast cancer in DESTINY-Breast09 Phase III trial astrazeneca.com ↗ |
| 2025-05-13 | Roche Global Development | Ten-year APHINITY data show Roche’s Perjeta-based regimen reduced the risk of death by 17% in people with HER2-positive early-stage breast cancer roche.com ↗ |
| 2025-04-21 | AstraZeneca | Enhertu plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy for patients with HER2-positive metastatic breast cancer astrazeneca.com ↗ |
| 2025-03-28 | Organon and Co | European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11 organon.com ↗ |
| 2024-09-30 | Organon and Co | Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11 organon.com ↗ |
| 2022-07-14 | Roche Global Development | Eight-year data from APHINITY study show Roche’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer roche.com ↗ |
| 2022-06-13 | Organon and Co | Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates organon.com ↗ |
| 2020-12-23 | Roche Global Development | European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer roche.com ↗ |
| 2020-11-13 | Roche Global Development | CHMP recommends EU approval of Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer roche.com ↗ |
| 2020-06-29 | Roche Global Development | FDA approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer roche.com ↗ |
| 2020-02-25 | Roche Global Development | FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer roche.com ↗ |
| 2019-12-12 | Roche Global Development | Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer roche.com ↗ |
| 2019-12-11 | Roche Global Development | APHINITY six-year results strengthen evidence of clinical benefit with Roche’s Perjeta-based regimen roche.com ↗ |
| 2019-09-13 | Roche Global Development | Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer roche.com ↗ |
| 2018-06-01 | Roche Global Development | European Commission approves Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence roche.com ↗ |
| 2018-04-27 | Roche Global Development | CHMP recommends EU approval of Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence roche.com ↗ |
| 2017-12-21 | Roche Global Development | FDA approves Roche’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer roche.com ↗ |
| 2017-09-29 | Roche Global Development | FDA grants Priority Review for Roche’s Perjeta (pertuzumab) for adjuvant treatment of HER2-positive early breast cancer roche.com ↗ |
| 2017-06-05 | Roche Global Development | APHINITY study shows Roche’s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer roche.com ↗ |
| 2017-03-02 | Roche Global Development | Phase III APHINITY study shows Roche’s Perjeta® regimen helped people with an aggressive type of early breast cancer live longer without their disease returning compared to Herceptin® and chemotherapy roche.com ↗ |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 332 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pertuzumab | “Patients received neoadjuvant chemotherapy consisting of paclitaxel (80 mg/m2, day 1 and 8 of each 21-day cycle, intravenous), trastuzumab (6 mg/kg on day 1 of each cycle...” PMID 41713473 ↗ Feb 2026318“Patient must have received continuous anti-HER2 targeted therapy (including Trastuzumab, Trastuzumab/Pertuzumab, Trastuzumab-Deruxtecan, T-DM1) for at least 2 years in any line...” NCT06450314 ↗ “In patients with ER-positive and HER2-positive breast cancer, the therapeutic potential of combining trastuzumab, pertuzumab, and pyrotinib-representing a triple-targeted...” NCT07290166 ↗ “Pertuzumab will be administered as an IV loading dose of 840 milligrams (mg) on day 1 of cycle 1 (1 cycle length = 21 days), and 420 mg Q3W on day 1 of subsequent cycles until...” NCT03811418 ↗ “Perjeta® with the general name Pertuzumab injection, is a recombinant humanized monoclonal antibody targeting the extracellular second domain of human epidermal growth factor...” NCT05985187 ↗ “Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.” NCT06884254 ↗ “Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer” PMID 42150145 ↗ May 2026 “patients will receive pertuzumab (RPH-051 or Perjeta® drug products) combined with trastuzumab and docetaxel according to the following scheme” NCT07386938 ↗ “Docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP)for 6 cycles, administered per USPI (Unites States Prescribing Information) Label” NCT05256745 ↗ “TCH-P Taxotere (docetaxel), Carboplatin, Herceptin (trastuzumab), Perjeta (pertuzumab) standard of care neoadjuvant chemotherapy regimen” NCT03387553 ↗ “Pertuzumab combined with docetaxel, carboplatin and trastuzumab (TCbHP) for neoadjuvant therapy of HR+/HER2+ breast cancer” NCT05430347 ↗ “SHR-A1811 4.8 mg/kg and pertuzumab 420 mg are administered intravenously every 3 weeks for 4 cycles as neoadjuvant therapy” NCT07307287 ↗ “Pertuzumab: initial loading dose 840 mg, maintenance dose 420 mg, intravenous infusion, administered once every 3 weeks.” NCT07589972 ↗ “Pertuzumab: on the first day of the 21 day cycle, the initial dose was 840mg, intravenous infusion was 60 minutes” NCT05969184 ↗ “EU Perjeta (Pertuzumab) , an antineoplastic agent, is a recombinant humanized monoclonal antibody” NCT06038539 ↗ “as intravenous pertuzumab with a loading dose of 840 mg and a maintenance dose of 420 mg on day 1” PMID 39612919 ↗ Nov 2024 “Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks” NCT01669239 ↗ “Group A received Inetetamab+Pertuzumab+TPC, while Group B received Inetetamab+Pyrotinib+TPC.” NCT06641544 ↗ “Combination therapy regimen: Pertuzumab combined with lenvatinib for neoadjuvant treatment” NCT07550972 ↗ “Pertuzumab is a humanized monoclonal antibody for the treatment of breast cancer.” PMID 35594017 ↗ May 2022 “fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection” NCT06276868 ↗ “Pertuzumab: 420-mg ( loading dose 840mg) ivgtt d1, 21 days per cycle,6 cycles.” NCT04215003 ↗ “containing 15 mL solution of 1200 mg of pertuzumab and 600 mg of trastuzumab.” NCT06172127 ↗ “nab-paclitaxel + carboplatin + trastuzumab + pertuzumab (PCbHP, control arm)” NCT07528716 ↗ “* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg(IV))D1” NCT03881878 ↗ “Pertuzumab initially at 840mg IV followed by 420mg IV every 21 days” NCT06278870 ↗ “Intravenous infusion, q3 week, SHR-A1811 combined with pertuzumab” NCT07377916 ↗ “pertuzumab (840 mg loading dose followed by 420 mg Q3W on Day 1)” NCT06548178 ↗ “Pertuzumab + Trastuzumab + Taxane (docetaxel or paclitaxel)” NCT06135714 ↗ “All participants will received trastuzumab and pertuzumab.” NCT04750122 ↗ “docetaxel, carboplatin, trastuzumab, and pertuzumab” NCT07239271 ↗ “pertuzumab 840 mg loading, then 420 mg, iv, q3w” NCT05346107 ↗ “docetaxel/carboplatin/trastuzumab/Pertuzumab” NCT04094896 ↗ “Pertuzumab 420mg(initial dose 840mg)” NCT05871918 ↗ “Drug: SHR-A1811 Drug: Pertuzumab” NCT06973525 ↗ “rhuMAb 2C4 (pertuzumab)” NCT00058539 ↗ “Drug: Pertuzumab” NCT06510465 ↗ “Pertuzumab” NCT05429684 ↗ |
| Known as | Combination product: Trastuzumab + Pertuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05132582 ↗ |
| Known as | Omnitarg | “RhuMab 2C4 (Omnitarg), a Recombinant Humanized Antibody to HER2” NCT02490475 ↗ |
| Known as | Perjeta | “This study will evaluate the safety, tolerability, and pharmacokinetics of the combination of rhuMab 2C4(Perjeta) and capecitabine (Xeloda) in participants with advanced solid...” NCT02494596 ↗18“Perjeta® with the general name Pertuzumab injection, is a recombinant humanized monoclonal antibody targeting the extracellular second domain of human epidermal growth factor...” NCT05985187 ↗ “TCH-P Taxotere (docetaxel), Carboplatin, Herceptin (trastuzumab), Perjeta (pertuzumab) standard of care neoadjuvant chemotherapy regimen” NCT03387553 ↗ “The other drug, pertuzumab (Perjeta), is also given to women with advanced HER2 positive breast cancer.” NCT02252887 ↗ “Pertuzumab (Perjeta®) is a fully humanized monoclonal antibody” NCT05385705 ↗ “pertuzumab [PERJETA™]” NCT00943670 ↗ “Pertuzumab (Perjeta®)” NCT05283837 ↗ “pertuzumab [Perjeta]” NCT02402712 ↗ |
| Known as | Pmab | “Trastuzumab (Tmab), pertuzumab (Pmab), and taxane has been a standard first-line treatment for recurrent or metastatic human epidermal growth factor (HER2)-positive breast...” PMID 32381018 ↗ May 2020 |
| Known as | QL1209 | “QL1209 (Pertuzumab Injection): First dose 840mg, then 420mg, every 3 weeks, for a total of 6 cycles” NCT07299890 ↗ |
| Known as | QL1209 (A pertuzumab biosimilar produced by Qilu Pharmaceutical Co., Ltd) | “QL1209 (A pertuzumab biosimilar produced by Qilu Pharmaceutical Co., Ltd)” NCT07187752 ↗ |
| Known as | rhuMAb 2C4 | “A Phase Ib, Open-Label, Multicenter Study of the Safety and Pharmacokinetics of the Combination of RhuMab 2C4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and...” NCT02494596 ↗7“A Phase II, Open-label, Multicenter Study to Evaluate the Effect of Tumor-based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Recurrent Non-Small...” NCT00063154 ↗ “An Open-Label, Multicenter Extension Study of Pertuzumab (rhuMAb 2C4) in Subjects Treated With Pertuzumab in a Previous Genentech-Sponsored Phase II Cancer Study” NCT00096941 ↗ “Pertuzumab (rhuMAb 2C4)” NCT00058552 ↗ |
| Known as | ZRC-3277 | “Pertuzumab (ZRC-3277)” NCT05283837 ↗ |
| Action | Inhibit | “Pertuzumab disrupts heterodimerization between human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, and HER4.” PMID 28057664 ↗ Apr 2017 |
| Modality | Monoclonal antibody | “rhuMAb 2C4 (Pertuzumab)” NCT00063154 ↗ |
| Route | Intravenous | “Participants received pertuzumab intravenously on Day 1 of every 3 week cycle for up to 1 year” NCT00063154 ↗ |
| Target | ERBB2 | “Pertuzumab, a human epidermal growth factor receptor 2 (HER2) -targeted monoclonal antibody” PMID 20124182 ↗ Feb 2010 |